The latest Vaccine Surveillance Report now extends efficacy data out to 15 weeks, and shows a continued fall in booster efficacy against symptomatic disease, particularly where AZ was the primary course (below).https://t.co/a2YczqzWMR
— John Roberts (@john_actuary) January 27, 2022
1/ pic.twitter.com/tAHnhU4kiP